3 results
The primary objective of this study is to determine if ambrisentan is effective in delaying disease progression and death in subjects with IPF.Secondary objectives include evaluation of the safety and effect of ambrisentan on development of…
This study is being conducted to collect additional data to describe the safety and tolerability of multiple cycles of IV administration of fosaprepitant daily for 3 consecutive days, concomitantly with a 5-HT3 antagonist, with or without…
To evaluate the effect of prolonged duration of (fos)aprepitant prophylaxis on the prevention of delayed CINV (complete remission in the 24-72 hours after the final dose of chemotherapy) in children. The current 3-day regimen is compared to a…